ArticleDiagnostic microbiology and infectious disease2019
Lack of efficacy of ivermectin for prevention of a lethal Zika virus infection in a murine system.
Article in Diagnostic microbiology and infectious disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04391127 (Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection), which is not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2.Fundamental & clinical pharmacology · 2021Pooled it
- Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.The Journal of antibiotics · 2020Pooled it
- Possible Role of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Recovery of Post-COVID-19 Anosmia.Infection and drug resistance · 2022Trial
- Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19.International journal of nanomedicine · 2021Trial
- Drug repositioning as a promising approach for the eradication of emerging and re-emerging viral agents.Molecular diversity · 2025Review
- Ivermectin Inhibits Zika Virus Replication in Vitro But Does Not Prevent Zika Virus Infection in Rhesus Macaques (Macaca mulatta).The American journal of tropical medicine and hygiene · 2025Article
- Article
- A Comprehensive Review of the Development and Therapeutic Use of Antivirals in Flavivirus Infection.Viruses · 2025Review
- An ivermectin - atorvastatin combination impairs nuclear transport inhibiting dengue infectioniScience · 2023Article
- Vector-Transmitted Flaviviruses: An Antiviral Molecules Overview.Microorganisms · 2023Review
- Article
- Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic.Osong public health and research perspectives · 2022Article
- Finding a chink in the armor: Update, limitations, and challenges toward successful antivirals against flaviviruses.PLoS neglected tropical diseases · 2022Review
- Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells.Antimicrobial agents and chemotherapy · 2022Article
- Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus.Therapeutic advances in vaccines and immunotherapy · 2022Review
- Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study.International immunopharmacology · 2021Article
- Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection.Current research in translational medicine · 2021Review
- Disease-drug and drug-drug interaction in COVID-19: Risk and assessment.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs.The pharmacogenomics journal · 2021Review
- Exploring status of emergency drugs and vaccine development in Covid-19 pandemic: an update.Virusdisease · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The antihelminthic drug ivermectin has been demonstrated to have antiviral activity against the Zika virus and other arboviruses in in vitro studies. The effectiveness of ivermectin for Zika virus infection, however, has never been studied in an animal model. In this study, ivermectin was found to be ineffective for prevention of a lethal infection with the Senegal strain of Zika virus in Ifnar1 knockout mice. In view of several study limitations, evaluation of ivermectin's anti-Zika virus activity in other animal models and against other Zika virus strains would be desirable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.